Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06629402 · ClinicalTrials.gov registry record · Phase 2

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

A Phase 2 study of Acute Pain, sponsored by Ensysce Biosciences.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
1
Study location

NCT06629402 is a Phase 2 study of Acute Pain that has completed, run by Ensysce Biosciences. The registered enrollment target is 16 participants, below the 268-participant average among 50 other Acute Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06629402, a Phase 2 study of Acute Pain, has completed, sponsored by Ensysce Biosciences.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG PF614

Study Locations (1)

Kansas

  • Dr. Vince Clinical Research - Overland Park

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2023-10-05
Est. Completion 2023-11-15
Phase Phase 2

Sponsor

Ensysce Biosciences

9 total trials

What the Registry Record Tells You About NCT06629402

The ClinicalTrials.gov registry entry for NCT06629402 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 50 other Acute Pain trials with a reported enrollment target (94% lower). The listed sponsor is Ensysce Biosciences, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06629402 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT06629402 about?

NCT06629402 is a clinical study titled "Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)". The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).

What is the current status of trial NCT06629402?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2023-10-05. Estimated completion is 2023-11-15.

What conditions does trial NCT06629402 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT06629402?

The interventions under investigation include: Placebo (DRUG), PF614 (DRUG).

Who is sponsoring clinical trial NCT06629402?

This trial is sponsored by Ensysce Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06629402 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.